PL372615A1 - Kompozycje farmaceutyczne zawierające modafinil - Google Patents

Kompozycje farmaceutyczne zawierające modafinil

Info

Publication number
PL372615A1
PL372615A1 PL03372615A PL37261503A PL372615A1 PL 372615 A1 PL372615 A1 PL 372615A1 PL 03372615 A PL03372615 A PL 03372615A PL 37261503 A PL37261503 A PL 37261503A PL 372615 A1 PL372615 A1 PL 372615A1
Authority
PL
Poland
Prior art keywords
pharmaceutical compositions
modafinil
modafinil pharmaceutical
potency
drug
Prior art date
Application number
PL03372615A
Other languages
English (en)
Other versions
PL216994B1 (pl
Inventor
Craig Heacock
Alpa Parikh
Piyush R. Patel
Original Assignee
Cephalon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30118520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL372615(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon, Inc. filed Critical Cephalon, Inc.
Publication of PL372615A1 publication Critical patent/PL372615A1/pl
Publication of PL216994B1 publication Critical patent/PL216994B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL372615A 2002-07-12 2003-07-11 Kompozycje farmaceutyczne zawierające modafinil PL216994B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39553702P 2002-07-12 2002-07-12
US10/616,776 US20040048931A1 (en) 2002-07-12 2003-07-10 Modafinil pharmaceutical compositions

Publications (2)

Publication Number Publication Date
PL372615A1 true PL372615A1 (pl) 2005-07-25
PL216994B1 PL216994B1 (pl) 2014-06-30

Family

ID=30118520

Family Applications (1)

Application Number Title Priority Date Filing Date
PL372615A PL216994B1 (pl) 2002-07-12 2003-07-11 Kompozycje farmaceutyczne zawierające modafinil

Country Status (23)

Country Link
US (2) US20040048931A1 (pl)
EP (1) EP1542666B1 (pl)
JP (1) JP4902959B2 (pl)
KR (2) KR101163768B1 (pl)
CN (1) CN100423716C (pl)
AT (1) ATE363899T1 (pl)
AU (1) AU2003259128B2 (pl)
BR (1) BR0312619A (pl)
CA (1) CA2491317C (pl)
CY (1) CY1107714T1 (pl)
DE (1) DE60314265T2 (pl)
DK (1) DK1542666T3 (pl)
EA (2) EA200600968A1 (pl)
ES (1) ES2285189T3 (pl)
IL (1) IL165835A0 (pl)
IS (1) IS2516B (pl)
MX (1) MXPA05000373A (pl)
NO (1) NO334450B1 (pl)
NZ (1) NZ537627A (pl)
PL (1) PL216994B1 (pl)
PT (1) PT1542666E (pl)
TW (1) TW200407111A (pl)
WO (1) WO2004006905A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000747A (es) 2000-07-27 2003-06-04 Teva Pharma Modafinilo cristalino y puro y proceso para prepararlo.
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
IL153098A0 (en) * 2002-11-26 2003-06-24 Chemagis Ltd Pharmaceutical compositions containing modafinil
FR2849029B1 (fr) * 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
CA2420180A1 (en) * 2003-02-28 2004-08-28 Bernard Charles Sherman Tablets comprising modafinil
WO2004082624A2 (en) * 2003-03-17 2004-09-30 Neurohealing Pharmaceuticals, Inc. Modafinil-based neurorehabilitation of impaired neurological function associated with injury
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
EP1516869A1 (en) 2003-09-19 2005-03-23 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20050137264A1 (en) * 2003-12-22 2005-06-23 Patel Ashish A. Modafinil compositions
US20060024370A1 (en) 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
EP1909573A4 (en) * 2005-07-21 2010-09-22 Neurohealing Pharmaceuticals I SHORT-TERM EFFECTIVE MODAFINIL COMPOSITIONS WITH A RAPID INITIAL EFFECT, AND METHOD FOR THEIR USE
KR101187461B1 (ko) * 2005-07-29 2012-10-02 반다 파마슈티칼즈, 인코퍼레이티드. 각성을 향상시키는 방법
WO2007098446A2 (en) * 2006-02-21 2007-08-30 Accu-Break Pharmaceuticals, Inc. Method for minimizing variation in dosage forms
JP2009543803A (ja) * 2006-07-12 2009-12-10 エラン・ファルマ・インターナショナル・リミテッド モダフィニルのナノ粒子製剤
DK2056811T3 (en) * 2006-08-14 2018-05-22 Neurohealing Pharmaceuticals Inc Modafinil-based treatment for premature ejaculation
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil
NZ592970A (en) * 2008-12-03 2013-05-31 Astellas Deutschland Gmbh Oral dosage forms of bendamustine
JP5718937B2 (ja) * 2009-12-25 2015-05-13 イノファーマックス インコーポレイテッド パーキンソン病を治療するための医薬組成物及びその調製方法
FR2987266B1 (fr) 2012-02-28 2014-12-19 Debregeas Et Associes Pharma Procede d'obtention d'une composition pharmaceutique a base de modafinil, composition pharmaceutique ainsi obtenue et son application
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
CN115835862B (zh) * 2020-07-10 2026-01-02 广东横琴新创益生物医药有限公司 治疗阿尔茨海默病的莫达非尼组合

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1570994A (en) * 1923-11-20 1926-01-26 William A Cook Spring-forming die
US4002718A (en) * 1974-10-16 1977-01-11 Arnar-Stone Laboratories, Inc. Gelatin-encapsulated digoxin solutions and method of preparing the same
FR2408345A1 (fr) * 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
GB1584462A (en) * 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
US4329363A (en) * 1978-09-08 1982-05-11 Merck & Co., Inc. Substituted mercapto acid amides and their use
IT1130924B (it) * 1980-03-06 1986-06-18 Secifarma Spa Procedimento per la preparazione di spironolattone micronizzato
FR2528038B2 (fr) 1982-06-04 1985-08-09 Lafon Labor Derives de benzhydrylsulfinylacetamide et leur utilisation en therapeutique
US4517179A (en) * 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
US4623588A (en) 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
US4713246A (en) * 1984-03-19 1987-12-15 Bristol-Myers Company Etoposide oral dosage form
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
DE3720493A1 (de) * 1987-06-20 1989-01-26 Nattermann A & Cie Arzneizubereitungen mit mikronisierten ebselen-kristallen
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
FR2663225B1 (fr) * 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2684875B1 (fr) 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
FR2697162B1 (fr) * 1992-10-23 1995-01-13 Lafon Labor Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
US5843347A (en) * 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
FR2702968B1 (fr) 1993-03-23 1995-06-23 Lafon Labor Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .
FR2706767B1 (pl) * 1993-06-22 1995-09-08 Lafon Labor
FR2708201B1 (fr) 1993-06-30 1995-10-20 Lafon Labor Utilisation de dérivés d'acétamide pour la fabrication de médicaments.
FR2707637B1 (fr) * 1993-06-30 1995-10-06 Lafon Labor Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique.
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
SI20624A (sl) 1998-12-18 2002-02-28 Abbott Laboratories Formulacija divalproeks natrija za kontrolirano sproščanje
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) * 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation
FR2804322B1 (fr) * 2000-01-31 2002-04-19 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies
US20010034373A1 (en) 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
MXPA03000747A (es) 2000-07-27 2003-06-04 Teva Pharma Modafinilo cristalino y puro y proceso para prepararlo.
BR0114814A (pt) * 2000-10-11 2005-01-25 Cephalon Inc Composições compreendendo composto de modafinila e seu uso
US7297346B2 (en) * 2001-05-25 2007-11-20 Cephalon Inc. Pharmaceutical formulations of modafinil
US20030055075A1 (en) * 2001-07-13 2003-03-20 Rubsamen Reid M. Programmable controlled release injectable opioid formulation
JP2005508939A (ja) * 2001-10-12 2005-04-07 エラン ファーマ インターナショナル，リミティド 即時放出および徐放特性を組み合わせて有する組成物
MY137846A (en) * 2002-07-08 2009-03-31 Ranbaxy Lab Ltd Processes for the preparation of oral dosage formulations of modafinil
IL153098A0 (en) * 2002-11-26 2003-06-24 Chemagis Ltd Pharmaceutical compositions containing modafinil
US20040167255A1 (en) * 2003-01-14 2004-08-26 Everlight Usa, Inc. Stabilizer composition

Also Published As

Publication number Publication date
NO20045533L (no) 2005-02-11
HK1077195A1 (en) 2006-02-10
AU2003259128A1 (en) 2004-02-02
EP1542666A1 (en) 2005-06-22
PT1542666E (pt) 2007-07-18
CN1668289A (zh) 2005-09-14
KR101163768B1 (ko) 2012-07-06
JP2005533114A (ja) 2005-11-04
EA200600968A1 (ru) 2007-02-27
DE60314265T2 (de) 2008-01-31
IS7595A (is) 2004-12-13
DE60314265D1 (de) 2007-07-19
JP4902959B2 (ja) 2012-03-21
MXPA05000373A (es) 2005-03-31
US20040048931A1 (en) 2004-03-11
US8580308B2 (en) 2013-11-12
BR0312619A (pt) 2005-04-19
ES2285189T3 (es) 2007-11-16
IL165835A0 (en) 2006-01-15
EA007562B1 (ru) 2006-12-29
US20070065517A1 (en) 2007-03-22
KR20050026475A (ko) 2005-03-15
AU2003259128B2 (en) 2008-12-04
DK1542666T3 (da) 2007-09-17
NO334450B1 (no) 2014-03-03
EP1542666B1 (en) 2007-06-06
KR20110092361A (ko) 2011-08-17
CY1107714T1 (el) 2013-04-18
ATE363899T1 (de) 2007-06-15
NZ537627A (en) 2006-11-30
CA2491317A1 (en) 2004-01-22
PL216994B1 (pl) 2014-06-30
IS2516B (is) 2009-06-15
CN100423716C (zh) 2008-10-08
CA2491317C (en) 2011-12-06
TW200407111A (en) 2004-05-16
WO2004006905A1 (en) 2004-01-22
EA200500190A1 (ru) 2005-06-30

Similar Documents

Publication Publication Date Title
CY1107714T1 (el) Φαρμακευτικες συνθεσεις μοδαφινιλιου
MX9602176A (es) Modafinilo teniendo tamaño de particulas definido.
TW200502005A (en) Pharmaceutical products
IL164217A0 (en) Pharmaceutical compositions containing water-soluble propofol and methods of administering same
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
AU2003295092A1 (en) Drug delivery particles and methods of treating particles to improve their drug delivery capabilities
HUP0402063A3 (en) Indole-2-carboxamides process for producing them, pharmaceutical compositions containing them and use thereof
TNSN05046A1 (en) Method of preparing dry powder inhalation compositions
AU2003269802A8 (en) Methods for producing submicron polytetrafluoroethylene powder and products thereof
IL163868A (en) Hemiasterlin derivatives and pharmaceutical compositions comprising them
AU2003257791A1 (en) Soild nano pharmaceutical formulation and preparation method thereof
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
AU2003246567A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
AU2003246566A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
AU2001296939A1 (en) Oral delivery method and composition for solid medications or dietary supplements in the form of solid particles
AU2003213402A1 (en) Powdery medicinal compositions for inhalation and process for producing the same
MY138052A (en) Modafinil pharmaceutical compositions
AU2003251303A1 (en) Pharmaceutical products and methods of manufacture
NO20043859L (no) Pulversammensetning inneholdende zaleplon med definert partikkelstorrelsesfordeling og farmasoytiske produkter derav
AU2003300694A1 (en) Pharmaceutical preparations on the basis of moisture-protected granules and a process for producing them
GB0214751D0 (en) Particle size reduction of poorly soluble drugs
AU2003229972A1 (en) Process for the treatment of particles for use in pharmaceutical formulations
HK1073062A (en) Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same
IL160412A0 (en) Methods and pharmaceutical compositions for immune deception, particularly in the treatment of cancer
AU2002237181A1 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy